Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival.

Literature DB >> 24695690

Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival.

Lili Ji¹, Yingze Wei², Tao Jiang³, Shuyang Wang².

Abstract

Due to emergence of resistant tumor populations, prognosis for metastatic colorectal cancer (CRC) patients remains poor and five-year survival rate is still very low. To guide clinicians in selecting treatment option for CRC patients, reliable markers predictive of poor clinical outcome are desirable. This study analyzed the correlation of NF-E2-related factor 2 (Nrf2), NAD(P)H quinine oxidoreductase 1 (NQO1), multidrug resistant protein 1 (MRP1), cmyc and p53 in CRC and their relationships to Duke's stage and clinical prognosis. 76 specimens of CRC tissues were immunohistochemically investigated using Nrf2, NQO1, MRP1, cmyc and p53 antibodies. IHC stain showed that Nrf2, NQO1, MRP1, cmyc and p53 were highly expressed in CRC tissues compared with adjacent non-tumor tissues. Significant positive correlations were found between the expression of Nrf2 and that of NQO1, MRP1, cmyc and p53. Moreover, there was significant correlation between the high level of Nrf2, NQO1, MRP1, p53 expression and Duke's stage, as well as poor clinical prognosis. We confirmed that Nrf2, NQO1, MRP1, and p53 expression exhibits considerable heterogeneity according to CRC clinical stage and prognosis. Nrf2 is the most promising biomarker in identifying a poor prognostic group of CRC.

Entities: Disease Gene Species

Keywords: Colorectal cancer (CRC); NAD(P)H quinine oxidoreductase 1 (NQO1); NF-E2-related factor 2 (Nrf2); cmyc; multidrug resistant protein 1 (MRP1); p53

Mesh：

Substances：

Year: 2014 PMID： 24695690 PMCID： PMC3971317

Source DB: PubMed Journal: Int J Clin Exp Pathol ISSN： 1936-2625

26 in total

1. The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant.

Authors: D Siegel; E M Bolton; J A Burr; D C Liebler; D Ross
Journal: Mol Pharmacol Date: 1997-08 Impact factor: 4.436

2. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic antioxidants.

Authors: L V Favreau; C B Pickett
Journal: J Biol Chem Date: 1991-03-05 Impact factor: 5.157

3. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors: K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal: Biochem Biophys Res Commun Date: 1997-07-18 Impact factor: 3.575

4. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase.

Authors: Manabu Furukawa; Yue Xiong
Journal: Mol Cell Biol Date: 2005-01 Impact factor: 4.272

Review 5. A family of drug transporters: the multidrug resistance-associated proteins.

Authors: P Borst; R Evers; M Kool; J Wijnholds
Journal: J Natl Cancer Inst Date: 2000-08-16 Impact factor: 13.506

Review 6. Quinone reductases multitasking in the metabolic world.

Authors: David Ross
Journal: Drug Metab Rev Date: 2004-10 Impact factor: 4.518

7. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.

Authors: David Siegel; Daniel L Gustafson; Donna L Dehn; Jin Yi Han; Preecha Boonchoong; Lawrence J Berliner; David Ross
Journal: Mol Pharmacol Date: 2004-05 Impact factor: 4.436

8. Nrf2 knockout enhances intestinal tumorigenesis in Apc(min/+) mice due to attenuation of anti-oxidative stress pathway while potentiates inflammation.

Authors: Ka Lung Cheung; Jong Hun Lee; Tin Oo Khor; Tien-Yuan Wu; Guang Xun Li; Jefferson Chan; Chung S Yang; Ah-Ng Tony Kong
Journal: Mol Carcinog Date: 2012-08-21 Impact factor: 4.784

9. An electrophile responsive element (EpRE) regulates beta-naphthoflavone induction of the human gamma-glutamylcysteine synthetase regulatory subunit gene. Constitutive expression is mediated by an adjacent AP-1 site.

Authors: H R Moinova; R T Mulcahy
Journal: J Biol Chem Date: 1998-06-12 Impact factor: 5.157

10. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.

Authors: S P Cole; G Bhardwaj; J H Gerlach; J E Mackie; C E Grant; K C Almquist; A J Stewart; E U Kurz; A M Duncan; R G Deeley
Journal: Science Date: 1992-12-04 Impact factor: 47.728

28 in total

Review 1. Clinical Relevance of Biomarkers of Oxidative Stress.

Authors: Jeroen Frijhoff; Paul G Winyard; Neven Zarkovic; Sean S Davies; Roland Stocker; David Cheng; Annie R Knight; Emma Louise Taylor; Jeannette Oettrich; Tatjana Ruskovska; Ana Cipak Gasparovic; Antonio Cuadrado; Daniela Weber; Henrik Enghusen Poulsen; Tilman Grune; Harald H H W Schmidt; Pietro Ghezzi
Journal: Antioxid Redox Signal Date: 2015-10-26 Impact factor: 8.401

2. Zinc finger protein 746 promotes colorectal cancer progression via c-Myc stability mediated by glycogen synthase kinase 3β and F-box and WD repeat domain-containing 7.

Authors: Ji Hoon Jung; Deok-Beom Jung; Hyunseok Kim; Hyemin Lee; Shi-Eun Kang; Sanjay K Srivastava; Miyong Yun; Sung-Hoon Kim
Journal: Oncogene Date: 2018-04-09 Impact factor: 9.867

3. Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells.

Authors: K Diehl; L-A Dinges; O Helm; N Ammar; D Plundrich; A Arlt; C Röcken; S Sebens; H Schäfer
Journal: Oncogene Date: 2017-08-28 Impact factor: 9.867

4. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors: David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal: Mod Pathol Date: 2019-08-30 Impact factor: 7.842

5. Effect of the Nrf2-ARE signaling pathway on biological characteristics and sensitivity to sunitinib in renal cell carcinoma.

Authors: Shiliang Ji; Yufeng Xiong; Xingxing Zhao; Yanli Liu; Li Qiang Yu
Journal: Oncol Lett Date: 2019-03-18 Impact factor: 2.967

Review 6. Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment.

Authors: Eui Jung Moon; Amato Giaccia
Journal: Free Radic Biol Med Date: 2014-11-29 Impact factor: 7.376

7. OKN-007 decreases free radical levels in a preclinical F98 rat glioma model.

Authors: Patricia Coutinho de Souza; Nataliya Smith; Oluwatomisin Atolagbe; Jadith Ziegler; Charity Njoku; Megan Lerner; Marilyn Ehrenshaft; Ronald P Mason; Bill Meek; Scott M Plafker; Debra Saunders; Nadezda Mamedova; Rheal A Towner
Journal: Free Radic Biol Med Date: 2015-06-26 Impact factor: 7.376